Decoy Therapeutics (NASDAQ:DCOY) Sees Significant Drop in Short Interest

Decoy Therapeutics (NASDAQ:DCOY) was the recipient of a significant drop in short interest in June. As of June 15th, there was short interest totaling 1,966 shares, a drop of 78.5% from the May 31st total of 9,158 shares. Approximately 0.4% of the shares of the stock are sold short. Based on an average daily trading volume, of 18,536 shares, the short-interest ratio is presently 0.1 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded Decoy Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday, June 12th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Decoy Therapeutics currently has an average rating of “Hold” and an average target price of $30.00.

Decoy Therapeutics Stock Down 6.8%

NASDAQ DCOY traded down $0.40 on Friday, hitting $5.52. 5,227 shares of the company were exchanged, compared to its average volume of 13,592. Decoy Therapeutics has a twelve month low of $4.32 and a twelve month high of $415.80. The company has a market cap of $2.94 million, a price-to-earnings ratio of -0.05 and a beta of 0.57. The company’s 50 day moving average price is $6.12.

Decoy Therapeutics (NASDAQ:DCOY) last released its earnings results on Friday, May 8th. The company reported ($4.18) earnings per share for the quarter. Equities research analysts expect that Decoy Therapeutics will post -12.97 earnings per share for the current fiscal year.

Decoy Therapeutics Company Profile

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577.